Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Accounts Payables (2020 - 2026)

Climb Bio filings provide 7 years of Accounts Payables readings, the most recent being $860000.0 for Q1 2026.

  • Quarterly Accounts Payables rose 10.68% to $860000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $860000.0 through Mar 2026, up 10.68% year-over-year, with the annual reading at $2.3 million for FY2025, 221.84% up from the prior year.
  • Accounts Payables hit $860000.0 in Q1 2026 for Climb Bio, down from $2.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.3 million in Q4 2025 and bottomed at $21000.0 in Q2 2022.
  • Average Accounts Payables over 5 years is $739705.9, with a median of $750000.0 recorded in 2022.
  • Peak annual rise in Accounts Payables hit 4080.95% in 2023, while the deepest fall reached 91.2% in 2023.
  • Climb Bio's Accounts Payables stood at $750000.0 in 2022, then tumbled by 91.2% to $66000.0 in 2023, then soared by 968.18% to $705000.0 in 2024, then surged by 221.84% to $2.3 million in 2025, then plummeted by 62.1% to $860000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Accounts Payables are $860000.0 (Q1 2026), $2.3 million (Q4 2025), and $477000.0 (Q3 2025).